Abstract
The introduction of recombinant DNA-synthesized human growth hormone in the mid-1980s, and its attendant unlimited supply, have led to wider application of growth hormone therapy in children. Over the past decade, the efficacy of growth hormone treatment in patients with Turner syndrome and chronic renal insufficiency, two conditions in which growth hormone secretion is normal, in improving growth velocity and final height, has also led to the consideration of growth hormone therapy in children with idiopathic short stature. Although thousands of patients with idiopathic short stature are currently being treated with growth hormone, the limited overall results available at this time do not show a significant improvement in final adult height despite an improvement in short-term growth velocity. Potential reasons for this outcome include 1) skeletal age advancing more rapidly than height age, 2) heterogeneity of the patient population comprising idiopathic short stature, 3) inherent inaccuracies of methodological tools, such as measurement of predicted adult height, and 4) a subset of children with idiopathic short stature who may, in fact, have partial growth hormone insensitivity. From a psychological perspective, the consensus of investigations in non-clinic-referred populations of psychosocial function in children with short stature do not indicate a disadvantage compared with children of normal height when socio-economic status is taken into consideration. These results, in conjunction with the minimal gains reported in behavioural measurements in idiopathic short children treated with growth hormone, question the traditional rationale that augmentation of growth velocity results in improvement in psychosocial well-being.
Similar content being viewed by others
References
Hintz RL. The prismatic case of Creutzfeldt-Jakob disease associated with pituitary growth hormone treatment. JClin Endocrinol Metab 1995; 80: 2298–2301.
Brown P. Human growth hormone therapy and Cruetzfeld-Jacob disease: a drama in three acts.Pediatrics 1988; 81: 85.
Furlanetto RWet al. Guidelines for the use of growth hormone in children with short stature. A report by the Drug and Therapeutics Committee of the Lawson Wilikins Pediatric Endocrine Soceity.J Pediatr 1995; 127: 857–867.
Rosenfeld RG, Frane J, Atrie KM. Six-yearold results of a randomized prospective trial of human growth hormone and oxandrolone in Turner syndrome.J Pediatr 1992; 121: 49–55.
Spiliotis BE, August GP, Hung Wet al. Growth hormone neurosecretory dysfunction: a treatable cause of short stature.JAMA 1984; 251: 2223–2230.
Rose SR, Ross JL, Uriarte Met al. The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency.N Engl J Med 1988; 319: 201–207.
Costin G, Kaufman FR, Brasel JA. Growth hormone secretory dynamics in subjects with normal staure.J Pediatr 1989; 115: 537–544.
Rosenfeld RG, Albertsson-Willand K; Cassorla Fet al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited.J Clin Endocrinol Metab 1995; 80: 1532–1540.
Ranke MB, Blank B. Is there an auxological basis for growth-promoting treatment with human growth hormone in short children?Acta Paediatr Scand [Supple] 1990; 367: 4–10.
Van Vliet G, Styne DM, Kaplan SL, Grumbach MM. Growth Hormone treatment for short stature.N Engl J Med 1983; 309: 1016–1022.
Hopwood NJ, Hintz RL, Gertner JMet al. Growth response of children with nongrowth-hormone deficiency and marked short stature during three years of growth hormone therapy.J Pediatr 1993; 123: 215–222.
Bramswig JG, Fasse M, Holthoff M-Let al. Adult height in boys and girls with untreated short stature and constitutional delay of growth and puberty: accuracy of five different methods of height prediction.J Pediatr 1990; 117: 886–891.
Loche S, Cambiaso P, Setzu Set al. Final height after growth hormone therapy in nongrowth-hormone-deficient children with short stature.J Pediatr 1994; 125: 196–200.
Kaplowitz PB. Effect of growth hormone therapy on final versus predicted height in short 12 to 16 year-old boys without growth hormone deficiency.J Pediatr 1995; 126: 478–480.
Guyda HJ. Use of growth hormone in children with short stature and normal growth hormone secretion: a growing problem.Trends Endocrinol Metab 1994; 5: 334–340.
Wit JM, Boersma B, deMuinck-Keizer-Schrama SMet al. Long-term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Dutch Growth Hormone Working Group.Clin Endocrinol 1995; 42: 365–372.
Lesage C, Walker J, Landler Fet al. Near normalization of adolescent height with growth hormone therapy in very short children without growth hormone deficiency.J Pediatr 1991; 119, 29–34
Saggese G, Cesaretti G, Barsanti S, Rossi A Combination treatment with growth hormone and gonadotropin-releasing hormone analogs, in short normal girls.J Pediatr 1995; 126: 468–473.
Balducci R, Toscano V; Mangiantini Aet al. Adult height in short normal adolescent girls treated with gonadotropin-releasing hormone analog and growth hormoneJ. Clin Endocrinol Metab 1995; 80: 3596–3600.
Attie KM, Carlsson LMS, Rundle AC, Sherman BM. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature.J Pediatr 1995; 127: 244–250.
Godddard AD, Covello R, Luoh S-Met al. Mutations of the growth hormone receptor in children with idiopathic short stature.N. Engl J Med 1995; 333: 1093–1098.
Carlsson LMS, Attie KM, Compton PGet al. Reduced concentration of serum growth hormone-binding protein in children with idiopathic short stature.J Clin Endocrinol Metab 1994; 78: 1325–1330.
Guevara-Aguirre J, Vasconez O, Martinez Vet al.A randomized, double blind, placebocontrolled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.J Clin Endocrinol Metab 1995; 80: 1393–1398.
Tanner JS.Catch-up and catch-down: a review.Growth, Genetics, and Hormones 1987; 3: 8–11.
Allen DB, Fost NC. Growth hormone therapy for short stature: panacea or pandora’s box?J Pediatr 1990; 117: 16–21.
Scarth LG, Gardiner HM, Valentine S McGhee AM. By taking thought: psychological studies of treated short normal children. In Stabler B, Underwood LE, eds.Growth, Stature and Adaption: Behavioral,Social and Cognitive Aspects of Growth Delay. University of North Carolina at Chapel Hill: 1994:107–121.
Vance MD, Ingersoll GM, Goden MP. Short stature in a noh-clinical sample: not a big problem. In: Stabler B, Underwood LE, eds.,Growth, Stature and Adaptation: Behavioural,Social and Cognitive Aspects of Growth Delay. University of North Carolina at Chapel Hill: 1994: 35–45.
Voss LD, Mulligan J. The short normal child in school: self-esteem, behaviour, and attainment before puberty (The Wessex Growth Study). In: Stabler B, Underwood LE, eds.Growth, Stature and Adaptation: Behavioral, Social and Cognitive Aspects of Growth Delay. University of North Carolina at Chapel Hill: 1994: 47–64.
Lifeshitz F, Moses N. Nutritional growth retardation. In: Lifshitz F, ed.Pediatric Endocrinology. New York: Marcel Dekker, Inc., 1990: 111–132.
Uhde TW. Growth Hormone dysregulation in nervous humans and animals: Practical and theoretical implications. In: Stabler B, Underwood LE, eds.Growth, Stature and Adaptation: Behavioral, Social and Cognitive Aspects of Growth Delay. University of North Carolina at Chapel Hill: 1994: 83–98.
Po Well, GF, Brasel JA, Raiti S, Blizzard RM. Emotional deprivation and growth retardation simulating idiopathic hypopituitarism. II. Endocrinlogic evaluation of the syndrome.N Engl J Med 1967; 276: 1279–1283.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Germak, J.A. Growth hormone therapy in children with short stature: Is bigger better or achievable?. Indian J Pediatr 63, 591–597 (1996). https://doi.org/10.1007/BF02730801
Issue Date:
DOI: https://doi.org/10.1007/BF02730801